We came across a bullish thesis on Autolus Therapeutics plc (AUTL) on wallstreetbets Subreddit Page by _Ukey_. In this article, we will summarize the bulls’ thesis on AUTL. Autolus Therapeutics plc (AUTL)’s share was trading at $3.20 as of Dec 3rd.
A scientist in a laboratory, working on developing a new cancer therapy.
Autolus Therapeutics is a biopharmaceutical company focused on developing innovative CAR-T cell therapies for the treatment of various cancers. Its flagship product, Aucatzyl (obecabtagene autoleucel), has recently gained attention with its FDA approval on November 8, 2024, for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). This approval marks a significant achievement for the company, positioning Aucatzyl as a promising new treatment option in the competitive CAR-T therapy market. The approval is supported by strong clinical data from the pivotal Phase 1b/2 FELIX study, which demonstrated an impressive 76.6% overall response rate, coupled with a low incidence of severe immune-related toxicities, further solidifying the therapy’s potential in the oncology space.
Financially, Autolus has seen substantial improvements in its cash position, with cash and cash equivalents increasing to $657.1 million as of September 30, 2024, up from $239.6 million at the end of 2023. This robust cash position, which has been bolstered by recent funding and investments, is expected to support the commercialization of Aucatzyl in r/r B-ALL as well as the advancement of the company’s broader pipeline of therapies. However, despite these positive developments, Autolus has also faced challenges. In Q3 2024, the company reported total operating expenses of $67.9 million, a significant increase from $42.9 million in the same period of 2023. As a result, the company posted a net loss of $82.1 million for Q3 2024, compared to $45.8 million in Q3 2023. These losses highlight the ongoing challenges in managing costs while advancing clinical and commercial operations. Nonetheless, Autolus believes its current cash reserves are sufficient to fund its key priorities, including the full launch of Aucatzyl.
On the technical side, the stock has shown mixed signals. While it is trading above its short-term and long-term moving averages, suggesting a potential bullish trend, other indicators, such as the Relative Strength Index (RSI) and the Stochastic Oscillator, suggest that the stock may be approaching oversold conditions, indicating potential upside. The Moving Average Convergence Divergence (MACD) is also below the signal line, indicating bearish momentum. Support and resistance levels have been identified, with support at $2.80 and resistance at $3.50. A breakout above $3.50 could signal a bullish reversal, while a drop below $2.80 could indicate further declines.
The bull case for Autolus centers around its regulatory success with Aucatzyl, the strong clinical data backing its flagship therapy, and the company’s solid cash position. Analysts have expressed optimism, with an average price target of $10.20, which suggests significant upside potential from the current stock price. However, the company faces several risks, including the intense competition in the CAR-T therapy market, with established players like Novartis and Gilead, and the increasing financial losses that could raise concerns about long-term profitability. Additionally, challenges in manufacturing, distribution, and market adoption of Aucatzyl could hinder its commercial success.
In conclusion, Autolus Therapeutics presents a compelling investment opportunity due to its recent FDA approval, promising clinical data, and solid financial position. However, the risks inherent in the biotechnology sector, particularly in the competitive CAR-T therapy market, mean that investors should be mindful of potential volatility. While the long-term outlook for the company appears positive, the stock’s recent volatility and execution risks necessitate careful consideration, making it a strong candidate for those with a high risk tolerance and a long-term investment horizon.
Autolus Therapeutics plc (AUTL) is not on our list of the 31 Most Popular Stocks Among Hedge Funds. As per our database, 20 hedge fund portfolios held AUTL at the end of the third quarter which was 24 in the previous quarter. While we acknowledge the risk and potential of AUTL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than AUTL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.